Ribociclib

AbbVie and Novartis are recommended as 'forever' dividend stocks, with AbbVie overcoming Humira's patent loss and Novartis focusing on innovative medicines post-spinoff, both offering strong dividend yields.

FDA approves Novartis' Kisqali for HR+/HER2- early breast cancer, reducing recurrence risk by 25.1% in NATALEE trial. Kisqali, combined with aromatase inhibitor, targets high-risk stage II and III patients, including those with node-negative disease. Treatment involves 400 mg daily for 3 weeks, followed by 1 week off, over 3 years.

Genentech to acquire Regor Therapeutics Group's next-gen CDK 4/6 inhibitors, including Phase I candidate RGT-419B for breast cancer treatment, aiming to compete with blockbuster drugs Ibrance, Verzenio, and Kisqali. Regor to receive $850m upfront and potential milestone payments. Genentech to handle global development, manufacturing, and commercialization; Regor to manage ongoing Phase I trials. Transaction expected to close Q4 2024.

Roche agreed to pay $850 million to acquire two experimental breast cancer drugs from Regor Therapeutics. These 'next-generation' CDK inhibitors, RGT-419B and another in early trials, aim to improve upon current CDK treatments by addressing resistance and reducing side effects. Roche plans to start a Phase 2 trial for RGT-419B in 2024, with Regor managing ongoing Phase 1 trials and Roche handling further development and commercialization.

Breast cancer treatment market employs various drugs, including chemotherapy, hormone therapies, targeted therapies, and immunotherapy. Market growth is driven by increased incidence, research advancements, early detection awareness, personalized medicine, and new drug classes. The market is projected to reach USD 49.2 billion by 2032, with major companies like Abbott, Merck, GSK, Novartis, Johnson & Johnson, Bristol-Myers Squibb, Sun Pharmaceutical, Pfizer, Teva Pharmaceutical, and AbbVie leading in innovation and geographical expansion.

FDA approval of adjuvant ribociclib (Kisqali) plus NSAI for high-risk HR+/HER2- breast cancer patients, based on NATALEE trial data showing improved iDFS (90.7% vs 87.6% at 36 months), addresses unmet need for those ineligible for abemaciclib. OS data were immature. Ribociclib's medium dose (400 mg) and 3-year treatment duration offer safety considerations. This approval broadens CDK4/6 inhibitor options, necessitating tailored discussions with patients.

FDA approves first at-home nasal spray flu vaccine, FluMist, available by prescription from online pharmacies.

FDA approves ribociclib for HR+/HER2– breast cancer, AMG 193 shows activity in MTAP-deleted tumors, pembrolizumab plus chemo for mesothelioma, neoadjuvant pembrolizumab/chemo boosts OS in TNBC, and experts discuss 2024 IASLC World Conference on Lung Cancer findings.

FDA approves Eli Lilly’s Ebglyss for eczema, Novartis’ Kisqali for early breast cancer, Merck’s Keytruda for malignant pleural mesothelioma, J&J’s Rybrevant for advanced lung cancer, and AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis.

MaxCyte partners with Kamau Therapeutics, Arvato Systems with Advanco, Revance Therapeutics' acquisition impacted by Crown Laboratories, Lifebit and CanPath strategic partnership, Kajeet and Avery Telehealth partnership. FDA approves Apple's sleep apnea detection, Roche's Ocrevus injectable, Novartis Kisqali, Lilly's EBGLYSS, issues alert on Astellas' Veozah, clears Eversense CGM system. Nura Bio raises $68 million, Arzeda $38 million. Cigna's Express Scripts sues FTC, Burson launches Decipher Health, short interest in healthcare stocks rises, Hill Holliday's Quest, Ascendis Pharma's positive Phase 3 results, WHO approves Bavarian Nordic's mpox vaccine, J&J's talc verdict overturned, Prime Therapeutics' new vision, Blue Matter acquires Sam Brown Inc.